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Adiponectin Gene Polymorphisms Modulate
Acute Adiponectin Response to Dietary Fat:
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Gianfranco Pagano,2 and Maurizio Cassader2
Factors underlying the independent association of nonalcoholic steatohepatitis (NASH) with
increased cardiovascular risk are unknown. Adiponectin polymorphisms predict cardiometa-
bolic risk in the general population. This association is not always mediated by low fasting
adiponectin levels, adipose tissue accumulation, or traditional risk factors. Adiponectin modu-
lates lipid metabolism and liver injury in nonalcoholic fatty liver disease (NAFLD) even in the
absence of obesity, dyslipidemia, and diabetes. We hypothesized adiponectin polymorphisms
may predispose to NAFLD and may increase cardiovascular risk by modulating circulating
lipoprotein and adiponectin response postprandially. The prevalence of adiponectin single-
nucleotide polymorphisms (SNPs) 45GT and 276GTwas assessed in 70 nonobese, nondiabetic,
normolipidemic NAFLD patients and 70 healthymatched controls; the impact of the adiponec-
tin SNPs was subsequently correlated to liver histology and postprandial adiponectin and li-
poprotein responses to oral fat load in a subgroup of 30 biopsy-proven patients with NASH and
30 controls. The 45TT and 276GT/TT genotypes were more prevalent in NAFLD patients than
in controls and independently predicted the severity of liver disease in NASH. In both patients
and controls, these genotypes exhibited a blunted postprandial adiponectin response and higher
postprandial triglycerides (Tg), free fatty acids (FFA), oxidized LDL (oxLDL), and VLDL levels
than their counterparts, despite comparable fasting adipokines, lipids, dietary habits, adiposity,
and insulin resistance. They were also independently associated, together with dietary polyun-
saturated fatty acid intake, with postprandial adiponectin response. IAUC adiponectin indepen-
dently predicted postprandial Tg, FFA, oxLDL, and intestinal and hepatic VLDL subfraction
responses in NASH. Conclusion: The at-risk adiponectin SNPs 45TT and 276GT are signifi-
cantlymore prevalent inNAFLDthan in the general population; they are associatedwith severity
of liver disease, with blunted postprandial adiponectin response, and with an atherogenic post-
prandial lipoprotein profile in NASH independently of fasting adipokine and lipid levels.
(HEPATOLOGY 2008;47:1167-1177.)
Nonalcoholic fatty liver disease (NAFLD) is themost common chronic liver disease in theWesternpopulation, encompassing a spectrum of histolog-
ical injury ranging from pure benign steatosis to progressive
necroinflammation (nonalcoholic steatohepatitis, NASH)
and fibrosis. NASH predicts incident cardiovascular disease
independently of classical risk factors, insulin resistance, and
metabolic syndrome, but mechanisms underlying this asso-
ciation are unclear, nor is it known which subjects with
NASHare at greater cardiovascular risk and should therefore
bemore aggressively treated.1,2 Altered adipokine action and
increased oxidative stress are candidate patogenetic mecha-
nisms inNAFLD. Among the different adipokines, low adi-
ponectin levels predict severity of liver disease in NAFLD,
even in the absence of diabetes and obesity.3,4
A genetic predisposition is indisputably present in
NAFLD, and several candidate genes affecting glucose
and lipid metabolism have been proposed.3,5
Two common single-nucleotide polymorphisms
(SNPs) in exon/intron 2 of the adiponectin gene (45TG
Abbreviations: Apo, apolipoprotein; FFA, free fatty acids; IAUC, incremental
area under postprandial curve; ISI, insulin sensitivity index; NAFLD, nonalcoholic
fatty liver disease; NASH, nonalcoholic steatohepatitis; oxLDL, oxidized LDL;
PUFAs, polyunsaturated fatty acids; SNP, single-nucleotide polymorphism; Tg,
triglycerides; TRLP, triglyceride-rich lipoprotein.
From the 1Gradenigo Hospital Turin, Italy; and 2Department of Internal Med-
icine, University of Turin, Turin, Italy.
Received July 25, 2007; accepted November 9, 2007.
Address reprints to: Giovanni Musso, Gradenigo Hospital, C. S. Regina Marghe-
rita 8, 10132 Torino, Italy. E-mail: giovanni_musso@yahoo.it.
Copyright © 2007 by the American Association for the Study of Liver Diseases.
Published online in Wiley InterScience (www.interscience.wiley.com).
DOI 10.1002/hep.22142
Potential conflict of interest: Nothing to report.
1167
and 276GT) have been associated with cardiometabolic
risk, with haplotypes 45TT and 276GT/TT carrying a
higher risk of type 2 diabetes and cardiovascular disease in
cross-sectional and prospective studies.6-10 Furthermore,
the same polymorphisms also predicted the thiazo-
lidinedione response independently of basal fasting adi-
ponectin levels.11 Mechanisms linking adiponectin SNPs
to cardiometabolic risk are unclear because these poly-
morphisms do not always associate with fasting adiponec-
tin level, overall/abdominal obesity, or other traditional
risk factors. Adiponectin enhances oxidation of free fatty
acid (FFA) and triglyceride-rich lipoprotein (TRLP) me-
tabolism independently of systemic inflammation or in-
sulin action.12
Exaggerated postprandial lipemia is an established car-
diovascular risk factor in diabetes.13 The liver takes up
circulating FFAs in a dose-dependent fashion and LDL
and remnants through the LDL-receptor and the liver-
related receptor protein (LRRP). Consistently, postpran-
dial lipid storage contributes substantially to liver
triglyceride (Tg) pool in NAFLD14 and the magnitude of
postprandial lipemia correlated with liver steatosis.4,14,15
The impact of polymorphisms in the adiponectin gene
on liver disease in NASH, as well as on the postprandial
adiponectin response and lipoprotein metabolism in
health and disease, has not been previously investigated.
Hypothesizing that the association of adiponectin
SNPs with cardiometabolic risk is mediated by liver fat
accumulation and that adiponectin polymorphisms mod-
ulate postprandial adiponectin response and lipoprotein
metabolism, we evaluated (1) the association of 2 com-
mon polymorphisms in the adiponectin gene with the risk
of NAFLD and (2) the impact of adiponectin SNPs on
the severity of liver disease and on postprandial adiponec-
tin response and lipoprotein metabolism in nonobese,
nondiabetic, normolipidemic patients with NASH.
Patients and Methods
Patient Selection. Because there are no data on
NAFLD, we based our study on large cohort studies of
Italian subjects.7,9 Considering a type I error of 0.05 and
a type II error of 0.20, at least 65 subjects with NAFLD
and 65 healthy controls were needed to detect a signifi-
cant between-group difference in the prevalence of the
45TG and 276GT adiponectin gene polymorphisms and
in circulating adipokines.
NAFLD was defined as persistently (at least 6 months)
elevated aminotransferases, the ultrasonographic presence
of bright liver without any other liver or biliary tract dis-
ease, with a daily alcohol consumption 20 g/day inmen
and  10 g/day in women,3 as assessed by a detailed
inquiry of patients and relatives and a validated question-
naire filled in daily for 1 week by the patients. Exclusion
criteria for other causes of fatty liver were: positive mark-
ers of viral, autoimmune, or celiac disease; abnormal cop-
per metabolism, serum 1-antitrypsin level, or thyroid
function tests; and exposure to occupational hepatotoxins
or to drugs known to be steatogenic or to affect glucose/
lipid metabolism. Because we aimed at identifying early
mechanisms predisposing to the future development of
cardiometabolic disease and different adipokines may in-
tervene at different stages of the development of diabetes
and obesity, obese and diabetic subjects were excluded
from our study.
Mutations in the hemochromatosis HFE and TRF2
genes were detected in patients and controls using a single
multiplex amplification reaction and premade, ready-to-
use test strips (Nuclear LaserMedicine,Milan, Italy). The
493 G/T microsomal triglyceride transfer protein
(MTP) gene polymorphism was assessed by PCR-RFLP
using 2-step nested PCR. The adiponectin45T/G and
276G/T polymorphisms were genotyped by amplifica-
tion of genomic DNA. The PCR product was digested at
37°C overnight with Smal or BsmI restriction enzyme,
respectively, and the digestion products were resolved by
electrophoresis in a 2% agarose gel.
The mean SE fibrosis score16 of the NAFLD group
was 0.64  0.21. To ensure biopsying subjects with the
progressive form ofNAFLD, that is, NASH, a liver biopsy
was proposed to patients with a high (0.676) or inde-
terminate (1.455-0.676) NAFLD fibrosis score. Thir-
ty-four patients fell within these categories, and 30
accepted undergoing a liver biopsy. All 30 patients had a
histological diagnosis of NASH, as proposed by Brunt.17
Liver iron concentration (LIC) and hepatic iron index
(HII) were determined from 2 mg of tissue dry weight by
atomic absorption spectroscopy.
To further rule out subclinical liver disease in controls,
in addition to a negligible alcohol intake (20 g/day in
men and 10 g/day in women) and normal abdomen
ultrasound, the upper healthy limit for ALT level was
lowered to30 U/L for men and20 U/L for women in
order to increase the negative predictive value of a normal
result.18,19
Patients and controls gave their consent to the study,
which was conducted according to the Helsinki Declara-
tion.
Alimentary Record. Patients and controls filled in
daily a dietary record for 1 week, according to the EPIC
protocol, analyzed using the WinFood database (Medi-
matica,–TE, Teramo, Italy) as previously described.4
Anthropometry. Percent body fat was estimated by
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the BIA method (TBF-202, Tanita, Tokyo, Japan),
closely correlating with dual X-ray absorptionmeasures.20
Cytokines. Serum tumor necrosis factor–, leptin,
and adiponectin were measured by sandwich ELISA
(R&D System Europe Ltd., Abingdon, UK). Resistin was
measured by an enzyme immunoassay (Bio Vendor labo-
ratory Medicine Inc., Brno, Czech Republic).
Oral Glucose Tolerance Test. After completion of
the alimentary record, patients and controls underwent a
standard 75-g oral glucose tolerance test. Then whole
body insulin sensitivity index (ISI) was calculated.21
Oral Fat Load. The 30 biopsied patients and 30 con-
trols comparable in age, body mass index (BMI), abdom-
inal waist circumference, ISI, insulin level, and dietary
habits underwent a 10-hour oral fat load test, as de-
scribed.4 Plasma total cholesterol (Chol), triglycerides
(Tg), and FFAs were measured by automated enzymatic
methods. The apolipoprotein E (ApoE) genotype was de-
termined by PCR amplification of genomic DNA using
specific oligonucleotide primers.
Measurement of TRLP Subfractions and Oxidized
LDL during Oral Fat Load Test. VLDL was isolated
through preparative ultracentrifugation and their Tg and
total Chol content were subsequently measured. One al-
iquot of plasma was brought to densities of 1,006 g/L by
adding a KBr solution (d 1330 g/L) and centrifuged at
105,000g for 21 hours at 10°C in a Beckman L8-70M
ultracentrifuge. Tg and total Chol concentration were
then determined in the lipoprotein fraction enzymati-
cally. The first, larger amount of blood (10 mL) was
drawn for subfractionating TRLP by ultracentrifugation
on a discontinuous density gradient. The sample was ul-
tracentrifuged in a Beckman L8-70M centrifuge at 20°C
in stages, allowing the separation of 2 VLDL fractions
with decreasing Sf values: VLDL 1, Sf  100; VLDL 2,
Sf 20-100. Chol and Tg content were measured in the
2 fractions.
ApoB48 and ApoB100 content of TRLP subfractions
were quantified by sodium dodecyl sulfate (SDS)–polyac-
rylamide gel electrophoresis using 3.9% gel.22 Nondelipi-
dated samples were reduced in SDS buffer for 4 minutes
at 96°C. Samples were applied to the gel and run at 40mA
in 0.025 M Tris, 0.192 M glycine, and 0.1% SDS. Gel
was stained with Silver Stain (Bio-Rad Laboratories). Be-
cause the chromogenicity of ApoB48 is similar to that of
ApoB100, a protein standard was prepared from LDL
isolated by sequential ultracentrifugation and used to
quantify ApoB100 and ApoB48. The bands were quanti-
fied by densitometry using Gel Doc equipment (Bio-Rad
Laboratories). Density values were assigned to the
ApoB100 bands of the standard LDL, and a standard
curve was constructed. The values were recalculated by
linear regression.
LDL-conjugated dienes, as markers of LDL lipoper-
oxidation, were determined by capillary electrophoresis,
as previously described.5
Statistical Analysis. Data are expressed as means 
SEMs. Differences were considered statistically signifi-
cant at P  0.05.
Differences between groups were analyzed by ANOVA
when variables were normally distributed; otherwise, the
Mann-Whitney test was used. The Bonferroni correction
was applied when significant between-group differences
were detected. Normality was evaluated by the Shapiro-
Wilk test. The chi-square test or Fisher’s exact test was
used to compare categorical variables.
Data from the oral fat load test were compared by
ANOVA and the Scheffe` post hoc test after log normal-
ization of skewed variables.
The area under the curve and the incremental area
under the postprandial curve (IAUC) of plasmaTg, FFAs,
and conjugated dienes during the oral fat load test were
computed by the trapezoid method.
Simple and multiple regression analyses were used to
estimate linear relationships between different variables
after log transformation of skewed data.
Logistic regression analysis was used to identify inde-
pendent predictors of IAUC adiponectin. The covariates
were age, sex, BMI, waist, ISI, fasting insulin, adiponec-
tin, SNPs 45GT and 276GT, and dietary polyunsatu-
rated fatty acid (PUFA) intake. Discrete variables were
divided into classes for analysis.
A logistic regression model was used to identify inde-
pendent predictors of severe (66% hepatocytes) steato-
sis, necroinflammatory grade 3, or fibrosis stage 3. The
covariates were age, BMI, waist, ISI, adiponectin SNP
polymorphism, fasting and postprandial adiponectin,
IAUC triglyceride/VLDL1 apoB48/apoB100, IAUC
LDL-conjugated dienes.
Results
Patient Characteristics. The prevalence of the
45TT haplotype was 59% in the controls versus 83%
in the NASH patients (P 0.004), 36% of the controls
were heterozygous 45GT carriers versus 15% of the
NASH patients ( P  0.008), and 5% of the controls
were homozygous GG carriers versus 2% of the NASH
patients (P  0.676). The prevalence of the 276GG
haplotype was 54% in the controls versus 24% in
NASH patients (P 0.001), 42% of the controls were
heterozygous 276GT carriers versus 73% of the NASH
patients (P  0.0002), and 4% of the controls were
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homozygous 276 TT carriers versus 3% of the NASH
patients (P  0.999). The genotype frequencies for
both adiponectin polymorphisms were in Hardy-
Weinberg equilibrium, and the allele frequencies were
consistent with published reports in a white popula-
tion.7,9 Because of the low prevalence of the 45GG and
276TT genotypes and of the overlapping clinical char-
acteristics of these subjects and heterozygous carriers,
they were combined with the GT genotype in all sta-
tistical analyses.
The main features of NASH patients and controls
grouped according to adiponectin SNP45TG and
276GT status are reported in Tables 1 and 2.
There were no significant differences in ApoE allelic
frequency or493GT MTP polymorphism among the 4
groups.
ISI, fasting insulin, and adiponectin were significantly
lower in patients with NASH than in controls, but they
did not differ by adiponectin genotype in NAFLD pa-
tients and controls (Tables 1 and 2).
Table 1. Baseline Characteristics of Controls and Patients with NAFLD Grouped According to Adiponectin SNP 45G/T
Characteristics
Controls
GT/GG
(n29)
Controls TT
(n41) P Controls
NASH GT/GG
(n12)
NASH TT
(n58) P NAFLD
Age (years) 37 2 40 2 0.307 43 2 38 3 0.201
Sex (%M) 67 68 0.890 68 72 0.815
Smokers (%) 34 31 0.618 36 33 0.715
% body fat 20 3 22 3 0.606 23.5 2.1 22.5 0.6 0.489
B.M.I. (kg/m2) 24.9 0.8 25.0 0.7 0.926 25.6 0.9 25.1 0.7 0.496
Waist (cm) 88 3 90 3 0.649 90 2 91 2 0.936
WHR 0.90 0.02 0.91 0.03 0.801 0.94 0.01 0.92 0.01 0.364
Systolic BP (mmHg) 122 3 124 2 0.711 128 2 127 2 0.818
Diastolic BP (mmHg) 78 3 77 2 0.774 88 1‡§ 86 1‡§ 0.475
Triglycerides (mg/dL)* 79 6 77 6 0.820 90 11 101 8*† 0.462
Total C (mg/dL) † 169 8 174 9 0.683 183 13 180 5 0.807
HDL-C (mg/dL) † 62 1 59 1 0.043 51 2‡§ 46 1†§ 0.014
LDL-C (mg/dL) † 99 8 102 8 0.792 113 9 115 6 0.867
Glucose(mg/dL) 88 3 90 3 0.649 94 1 97 1 0.334
Insulin (U/mL) 4.8 1.3 4.5 1.8 0.901 9.9 1.6‡§ 12.9 1.2‡§ 0.263
Whole body ISI 8.59 1.03 7.92 0.97 0.644 4.98 0.91‡§ 4.18 0.46‡§ 0.406
AST (U/L) 18 3 22 3 0.593 51 5‡§ 63 2‡§ 0.205
ALT (U/L) 19 4 20 3 0.891 72 9‡§ 94 4‡§ 0.023
GGT (U/L) 38 6 35 8 0.672 68 13‡§ 109 7‡§ 0.010
TNF- (pg/mL) 1.28 0.11 1.12 0.09 0.262 1.34 0.36 1.09 0.11 0.256
Adiponectin (ng/mL) 12843 1106 10914 983 0.316 6469 691‡§ 5228 514‡§ 0.299
Leptin (pg/mL) 1819 612 1783 749 0.962 1680 148 1594 146 0.895
Resistin (ng/mL) 3.97 0.83 4.29 0.62 0.754 3.92 0.77 4.15 0.31 0.752
ApoE genotype(%)
2-3 8 7 0.918 12 10 0.931
3-3 83 85 0.984 70 60 0.638
3-4 9 8 0.879 18 20 0.719
493 GT MTP genotype(%) GG 48 51 0.899 51 58 0.873
GT/TT 52 49 0.911 50 42 0.694
abdominal obesity (% subjects) 7 16 0.452 20 24 0.976
IGR (% subjects) 8 18 0.285 34*† 39*† 0.855
Hypertension (% subjects) 31 39 0.444 68† 65*† 0.786
Low HDL-C (%) 16 9 0.437 16*† 31† 0.603
High Tg (% subjects) 12 8 0.989 15 18*† 0.689
subjects with MS (%) 17 21 0.891 37*† 41*† 0.946
Steatosis (% hepatocyte)§§ — — — 21 4 43 5 0.008
Necroinflammatory grade§§ — — — 1.3 0.1 2.7 0.3 0.009
Fibrosis stage§§ — — — 1.1 0.3 2.9 0.4 0.006
Data are presented as mean  SEM. Abbreviations: BP, blood pressure; ISI, insulin sensitivity index; total C, total cholesterol; HDL—C, HDL cholesterol; LDL—C, LDL
cholesterol; WHR, waist—on—hip ratio; Tg, triglyceride; MTP, microsomal triglyceride transfer protein; IGR, impaired glucose regulation; MS, metabolic syndrome.
*P  0.05 vs. controls TT
†P  0.05 vs. controls GT/GG
‡P  0.001 vs. controls TT
§P  0.001 vs. controls GT/GG
§§ in biopsied patients.
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Plasma high-density lipoprotein–cholesterol (HDL-C)
was lower in NASH patients than in controls; NASH pa-
tients with SNP 45TT and 276GT/TT had lower HDL-C
levels than did those with the other genotypes (Table 1).
The prevalence of metabolic syndrome (ATP III crite-
ria) was higher in NASH patients than in controls but did
not differ by adiponectin genotype in the 2 groups (Ta-
bles 1 and 2).
To further assess the combined effects of the 2 adiponec-
tin SNPs on baseline characteristics, carriers of the haplotype
45TT276GT/TT were grouped together and compared
with the other haplotypes. The prevalence of haplotype
45TT276GT/TT was significantly higher in NASH pa-
tients than in controls: 64%versus 28%(P0.0002).Apart
from HDL-C, there were no significant between-haplotype
differences in the main anthropometric, metabolic, and di-
etary parameters between 45TT276GT/TT carriers and
their counterpart haplotypes in both theNASH and control
groups (not shown).
Histopathology. Fatty infiltration was mild (involv-
ing 5%-33% of hepatocytes) in 33% of patients with
NASH, moderate (33%-66% of hepatocytes) in 37%
Table 2. Baseline Characteristics of Controls and Patients with NAFLD Grouped According to Adiponectin SNP 276G/T
Characteristic
Controls
GG (n38)
Controls GT/TT
(n32) P Controls
NASH GG
(n17)
NASH GT/TT
(n53) P NAFLD
Age (years) 38 2 39 3 0.726 39 2 41 2 00.590
Sex (%M) 68 65 0.915 70 71 00.970
Smokers (%) 32 36 0.683 44 30 00.478
% body fat 21 3 22 2 0.792 23.4 2.0 22.3 2 00.767
B.M.I. (kg/m2) 25.0 0.9 24.9 0.7 0.538 25.2 0.4 24.6 0.4 00.936
Waist (cm) 88 2 89 3 0.719 88 2 91 3 00.420
WHR 0.90 0.02 0.91 0.03 0.771 0.91 0.02 0.93 0.02 00.480
Systolic BP (mmHg) 125 3 122 3 0.534 125 4 128 2 00.475
Diastolic BP (mmHg) 76 3 79 3 0.485 87 2‡§ 87 1‡§ 00.999
Triglycerides (mg/dL)* 76 5 80 6 0.617 83 10 102 8*† 00.215
Total C (mg/dL)† 167 9 174 8 0.639 180 7 181 6 00.930
HDL—C (mg/dL)† 62 1 58 1 0.010 55 2‡§ 49 1†§ 00.006
LDL-C (mg/dL)† 104 8 106 6 0.712 119 5 114 6 00.649
Glucose(mg/dL) 86 3 88 3 0.699 96 3 97 3 00.857
Insulin (U/mL) 4.3 1.6 4.0 1.3 0.598 12.2 2.1‡§ 12.8 1.2‡§ 00.805
Whole body ISI 8.19 1.62 8.03 0.94 0.791 4.56 1.14‡§ 3.89 0.26‡§ 00.398
AST (U/L) 16 2 18 3 0.568 46 4‡§ 59 2‡§ 00.342
ALT (U/L) 20 4 19 4 0.735 70 5‡§ 88 4‡§ 00.021
GGT (U/L) 37 12 40 11 0.813 68 16‡§ 110 15‡§ 00.137
TNF- (pg/mL) 1.13 0.11 1.06 0.08 0.690 1.33 0.23 1.07 0.16 00.386
Adiponectin (ng/mL) 11850 710 10591 670 0.498 5905 869‡§ 5469 552‡§ 00.445
Leptin (pg/mL) 1617 734 1749 812 0.904 1834 192 1626 146 00.455
Resistin (ng/mL) 3.78 0.68 4.01 0.70 0.691 3.86 0.33 4.68 0.39 00.200
ApoE genotype(%)
2-3 9 7 0.947 12 8 0.612
3-3 80 90 0.319 63 76 0.579
3-4
493 GT MTP genotype (%) 11 3 0.363 25 16 0.361
GG 40 53 0.325 64 69 0.839
GT/TT 60 47 0.386 36 31 0.996
abdominal obesity(% subjects) 9 17 0.455 25 22 00.895
IGR (% subjects) 11 17 0.987 38*† 39*† 00.838
Hypertension(% subjects) 34 37 0.976 62† 65*† 00.817
Low HDL-C (%) 6 17 0.234 13*† 35† 00.168
High Tg(% subjects) 9 10 0.898 19 18*† 00.736
subjects with MS (%) 17 23 0.553 43*† 39*† 0.953
Steatosis(% hepatocyte)§§ — — — 18 4 45 6 0.004
Necroinflammatorygrade§§ — — — 1.3 0.1 2.8 0.4 0.009
Fibrosis stage§§ — — — 1.2 0.1 2.9 0.4 0.006
Data are presented as mean  SEM. Abbreviations: BP, blood pressure; ISI, insulin sensitivity index; total C, total cholesterol; HDL-C, HDL cholesterol; LDL-C, LDL
cholesterol; WHR, waist-on-hip ratio; Tg, triglyceride; MTP, microsomal triglyceride transfer protein; IGR, impaired glucose regulation; MS, metabolic syndrome.
*P  0.05 vs. controls TT
†P  0.05 vs. controls GT/GG
‡P  0.001 vs. controls TT
§P  0.001 vs. controls GT/GG
§§ in biopsied patients.
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of patients, and severe (66% of hepatocytes involved)
in 30% of subjects. Necroinflammatory activity was
grade 1 in 30% of patients, grade 2 in 33%, and grade
3 in 37%.
Fibrosis was stage 0 in 17% of patients, stage 1 in 27%
of patients, stage 2 in 27%, and stage 3 in 29%; cirrhotic
changes were absent (Table 1). Liver iron concentration
was 18  5 mol/g dry weight, and hepatic iron index
was 0.52 0.06.
The severity of liver fatty infiltration, median necroin-
flammatory grade, and median fibrosis stage were higher
in SNP 45TT and SNP 276 GT/TT carriers than in the
other genotypes (Tables 1 and 2).
Similarly, 45 TT276GT/TT carriers with NASH
had a significantly higher severity of liver fat infiltration,
necroinflammation, and fibrosis than the other haplo-
types (not shown). Liver iron concentration and hepatic
iron index did not differ by adiponectin SNP.
Alimentary Record. Daily total energy and macronu-
trient intake of patients with NASH and controls were sim-
ilar: total calories, 2,466 99 versus 2,503 118 kcal, P
0.785; carbohydrate, 51%  2% versus 48%  2% kcal,
P0.291; protein, 16%3%versus 19%3%kcal,P
0.481; fat, 32% 3% versus 33% 3% kcal, P 0.814.
The NASH group consumed more saturated fat and
less polyunsaturated fat than did controls, when expressed
as both percentage of total calories and percentage of total
fat intake, as previously reported: saturated fatty acids
(SFAs), 12.2% 0.5% versus 10.2% 0.4% total kcal,
P 0.0002; PUFA, 3.6% 0.2% versus 5.2% 0.2%
total kcal, P  0.0001. Polyunsaturated to saturated fat
(P/S) ratio was also lower in NASH patients than in con-
trols: 0.30 0.02 versus 0.50 0.03; P  0.0001.
NASH patients also had a significantly lower daily in-
take of antioxidant vitamin A (638 71 versus 1,104
107 mg, P 0.008), vitamin C (116 14 versus 152
10 mg, P  0.038), and vitamin E (5.9  0.6 versus
9.6 0.8 mg, P  0.0009).
Daily alcohol intake was similar in the 2 groups: 11
2 versus 12 2 g; P  0.782.
There was no difference in daily antioxidant intake or
in any other macro/micronutrient intake by adiponectin
genotype in the NASH and control groups (not shown ).
Oral Fat Tolerance Test. Plasma adiponectin signif-
icantly increased in controls, whereas it decreased in
NASH patients (Fig. 1A–C).
In controls, postprandial adiponectin increase was sig-
nificantly lower in those with the SNP 45TT and SNP
276 GT/TT genotypes than the other genotypes; in
NASHpatients, the drop in postprandial adiponectin was
deeper in SNP 45TT and SNP 276GT/TT carriers than
in those with the other genotypes (Fig. 1A–C).
Fig. 1. Oral fat load test. Postprandial adiponectin response in pa-
tients and controls grouped according to SNP 45GT (A), SNP 276GT (B),
and combined 45GT/276GT (C) genotypes. Data are presented as
mean  SEM; *P  0.05 versus basal; P  0.01 versus basal; ŒP 
0.05 versus controls GT/GG;P 0.05 controls GT/GG versus controls
TT; P  0.05 NASH GT/GG versus NASH TT.
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Postprandial plasma Tg, FFAs, and LDL-conjugated
diene responses were significantly higher in the NASH
group than in controls. In the NASH and control groups,
SNP 45TT and SNP 276GT/TT carriers displayed sig-
nificantly higher postprandial Tg, FFAs, and LDL-conju-
gated diene responses than did those with the other
genotypes (Fig. 2A-B; Table 3).
Patients with NASH had higher postprandial intes-
tinal and hepatic VLDL1 and VLDL2 responses than
did controls. Postprandial VLDL1 and VLDL2 re-
sponses of both intestinal and hepatic origin were
higher in SNP 45TT and SNP 276GT/TT carriers
than in their counterpart genotypes in both patient and
control groups (Fig. 3A–D). The simultaneous pres-
ence of SNP 45TT and SNP 276GT/TT had an addi-
tive effect on postprandial adiponectin, lipid, and
lipoprotein responses in both patients and controls
(Fig. 1C; Table 3).
Correlative Analysis. The main correlations between
anthropometric, metabolic, and dietary parameters in pa-
tients with NASH are shown in Online Supplemental
Material Table 1.
On multiple regression analysis, only fasting ( 
0.39, P 0.033), IAUC adiponectin (0.48, P
0.008), and IAUC VLDL1 apoB48 (  0.51, P 
0.002) predicted IAUC Tg.
On multiple regression analysis, IAUC FFA was pre-
dicted by IAUC VLDL1 apoB48 ( 0.47, P 0.009),
and IAUC adiponectin (  0.53, P  0.001) pre-
dicted IAUCFFA. IAUCLDL-conjugated diene was pre-
dicted by IAUC VLDL1 apoB48 (  0.44, P  0.02)
and IAUC adiponectin (0.51, P 0.002). IAUC
VLDL1 apoB48 was independently predicted by fasting
(  0.44, P  0.02) and postprandial adiponectin
(  0.51, P  0.002). IAUC VLDL1 apoB100 was
independently predicted by fasting (  0.42, P 
0.03) and IAUC adiponectin (  0.48, P  0.008).
IAUCVLDL2 apoB48 was independently predicted only
by IAUC adiponectin (  0.49, P  0.007). IAUC
VLDL2 apoB100 was independently predicted by fasting
(  0.45, P  0.01) and postprandial adiponectin
( 0.49, P  0.007).
On logistic regression analysis, SNP 45TG (OR 3.8,
CI 2.3-6.8, P  0.009), SNP 276GT (OR  3.6, CI
2.2-5.7, P 0.004), and dietary PUFA intake (expressed
as % fat: OR 2.0, CI 1.5-3.1, P 0.02) independently
predicted postprandial adiponectin response in the lowest
quartile.
Severe hepatic steatosis was independently predicted
by SNP 276GT/TT (OR 3.5, CI 2.1-6.9, P 0.009),
SNP 45TT (OR 2.0, CI 1.6-4.5, P 0.02), and IAUC
VLDL1 apoB48 (OR 2.4, CI 1.9-5.3, P 0.011). The
presence of haplotype 45TT/276TTGT carried a 4.2-
fold increased risk (CI 2.9-7.0, P  0.006) of severe ste-
atosis.
Necroinflammatory grade 3 was predicted by SNP
276 GT/TT (OR  2.2, CI 1.5-5.3, P  0.01) and
IAUC LDL-coniugated dienes (OR 1.9, CI 1.3-4.9,
P  0.02). Haplotype 45TT/276TTGT carried a
3.2-fold increased risk (CI 1.7-5.2, P  0.008) of
necroinflammatory grade 3.
Stage 3 fibrosis was predicted by SNP 45TT (OR 
2.1, CI 1.8-5.7, P 0.01), SNP 276GT/TT (OR 1.9,
CI 1.5-4.6, P  0.015), and IAUC LDL-conjugated
dienes (OR  2.5, CI 1.8-6.0, P  0.009). Haplotype
45TT/276TTGT carried a 4.0-fold increased risk (CI
2.1-6.7, P  0.004) of fibrosis stage 3.
Discussion
The main findings of our study are:
1. Two common SNPs in adiponectin gene are signif-
icantly associated with the presence of NAFLD in nono-
Fig. 2. Oral fat load test. Postprandial plasma Tg and FFA responses, and
LDL-conjugated diene responses in patients and controls grouped according
to SNP 45GT. Data are presented as mean SEM; *P 0.05 versus basal;
P  0.01 versus basal; Œ P  0.05 versus controls GT/GG;P  0.05
controls GT/GG versus controls TT; P 0.05 NASH GT/GG versus NASH TT.
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bese, nondiabetic, normolipidemic subjects.
2. These 2 adiponectin SNPs also predict the severity
of liver disease and postprandial serum adiponectin and
lipoprotein responses in biopsy-proven NASH.
3. Adiponectin SNPs modulate postprandial adi-
ponectin response and lipoprotein metabolism in healthy
controls as well; in fact, 45TT and 276GT/TT genotypes
displayed a blunted postprandial adiponectin increase
and a more atherogenic lipid profile, with possible impli-
cations for primary prevention of hepatometabolic dis-
ease.
We report for the first time the association of 2 com-
mon SNPs of the adiponectin gene with the presence and
severity of NAFLD. Adiponectin SNPs 45TG and
276GT previously have been associated with an increased
cardiometabolic risk in different population-based stud-
ies, an effect often but not always associated with abdom-
inal/overall adiposity and lower adiponectin levels.7,9-11,23
In our nonobese, nondiabetic, normolipidemic popula-
tion, SNP 45TT and 276GT/TT carriers had a signifi-
cantly increased prevalence and severity of NAFLD than
the other genotypes, despite comparable fasting adipo-
kines, adiposity, insulin resistance, and dietary habits. Al-
though the cross-sectional nature of our study prevents
causal inference, it is intriguing to speculate that the asso-
ciation between these polymorphisms and the metabolic
complications in large population-based cohort studies
may be initiated by liver fat accumulation.
Our data provide a novel mechanism linking adi-
ponectin SNPs to fatty liver, that is, the acute modu-
lation of postprandial adiponectin response to fat
ingestion. Plasma adiponectin promptly increased
postprandially in controls, whereas NASH subjects
showed a much smaller increase or even a decrease in
plasma adiponectin (Fig. 1A–C). In both patients and
controls adiponectin polymorphisms were the main
predictors of postprandial adiponectin responses, to-
gether with dietary PUFA intake. Mechanisms under-
lying the differences in adiponectin responses between
NASH patients and controls and among different
SNPs are unclear. The finding of reduced adiponectin
mRNA expression in omental adipocytes from 45T
allele carriers compared to G-allele carriers24 suggests
reduced mRNA transcription or stability may underlie
Fig. 3. Oral fat load test. Postprandial VLDL apoB48 and apoB100 subfraction responses in patients with NASH and controls grouped according
to SNP 45GT. Data are presented as mean  SEM; *P  0.05 versus basal;3P  0.01 versus basal; Œ P  0.05 versus controls GT/GG;P 
0.05 controls GT/GG versus controls TT; P  0.05 NASH GT/GG versus NASH TT.
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the genetic associations described. Alternatively, these
SNPs may be in linkage disequilibrium with another
functional locus affecting lipoprotein metabolism and
lipid peroxidation. Because adipocytes take up FFAs
and oxLDL by CD36 receptor and oxidative stress ad-
versely affects adiponectin secretion,25 a reduced adi-
ponectin response with high-risk polymorphisms
would be a consequence of exaggerated postprandial
lipemia, thus perpetuating the vicious circle.
Patients with NASH consumed fewer PUFAs and
more SFAs than did controls, and PUFA intake was asso-
ciated with fasting and postprandial adiponectin. The
type and amount of dietary fat modulates adipocyte func-
tion, with PUFAs exerting a beneficial effect on adiponec-
tin secretion and hepatic steatosis.26-30 Animal models
suggest NASH is characterized by an adaptive failure to a
high-fat (mainly saturated) diet, a condition accompanied
by higher oxidative stress and lower adiponectin levels
than pure steatosis.31-33 The ability of adiponectin levels
to increase following a fat meal can be seen as an acute
adaptive mechanism enhancing FFA disposal and TRLP
catabolism. This compensatory mechanism is modulated
by genetic factors and is compromised to a higher extent
when wrong dietary habits are superimposed on an unfa-
vorable genetic background. When a wrong diet is super-
imposed on an unfavorable genetic background,
adipocytes lose their “compensatory” ability to acutely
increase adiponectin secretion in response to a fat load.
The loss of this “metabolic flexibility” would be an early
sign of adipocyte dysfunction and would lead to exagger-
ated postprandial lipemia, enhanced FFA, and lipid up-
take by the liver and adipose tissue,14,15 eventually
resulting in NAFLD, visceral obesity, and lower fasting
adiponectin levels.
Despite comparable fasting plasma lipids, adiposity,
and insulin resistance, 45TT and 276GT/TT geno-
types displayed higher postprandial TRLP and oxLDL
levels than the other genotypes in both patients and
controls. This highly atherogenic postprandial lipopro-
tein profile may partially account for the increased
atherogenic risk in NASH, independent of insulin re-
sistance, metabolic syndrome, or other traditional risk
factors.2 Interestingly, adiponectin SNPs had similar
fasting plasma adiponectin levels, thus suggesting that
adiponectin genotyping adds more information on in-
dividual cardiometabolic status than fasting adiponec-
tin measurement.11,24
The comparison of NASH subjects with healthy
controls also suggests that when other factors (i.e., in-
sulin resistance, hypoadiponectinemia, or wrong di-
etary habits) are superimposed on a high-risk genotype,
the higher fluxes of Tg and FFA and the defective
TRLP clearance of the insulin resistant state result in
more pronounced lipoprotein accumulation and li-
poperoxidation than with the other genotypes, thus
Table 3. Oral Fat Load Parameters of Controls and Patients with NASH Grouped According to Carrying Status of Adiponectin
45-276 GT Haplotype
Parameter Haplotype 45276 G/T
P
controls
Haplotype 45276 G/T
P NASH
Controls Other
haplotypes
(n20)
Controls 45
TT276 GT/TT
(n10)
NASH Other
haplotypes (n17)
NASH 45 TT276
GT/TT (n13)
Fasting adiponectin (ng/mL) 12390 2128 10513 1582 0.510 6174 1292‡§ 4971 1349‡§ 0.364
IAUC adiponectin (ng/mL x hr) 29564 4109 5953 1138 0.0002 972 691‡§‡§ 12107 2183‡§ 0.0003
Fasting Tg (mg/dL)* 68 6 75 8 0.498 81 11 105 13† 0.201
IAUC Tg (mg/dL x hr)* 182 32 68 23 0.021 558 61‡§ 264 43*† 0.0001
Fasting FFA (mMol/L) 0.42 0.11 0.51 0.13 0.162 1.04 0.20‡§ 1.18 0.24‡§ 0.566
IAUC FFA(mMol/L x hr) 0.40 0.16 1.28 0.21 0.003 3.01 0.86‡§ 6.28 1.12‡§ 0.009
Fasting VLDL1 ApoB48 (mg/dL) 2.01 0.46 2.31 0.50 0.689 6.32 1.13‡§ 6.09 1.25‡§ 0.893
IAUC VLDL1 ApoB48 (mg/dL x hr) 1.39 0.33 6.02 0.97 0.00007 11.52 1.98‡§ 32.13 2.96‡§ 0.00002
Fasting VLDL1 ApoB100 (mg/dL) 4.79 1.39 5.04 1.67 0.714 5.74 1.58 6.02 1.89 0.811
IAUC VLDL1 ApoB100 (mg/dL x hr) 1.78 0.29 6.08 1.17 0.0002 9.03 1.66‡* 28.94 4.39*§ 0.0001
Fasting VLDL2 ApoB48 (mg/dL) 0.77 0.36 0.84 0.31 0.563 1.89 0.56*† 1.67 0.64*† 0.698
IAUC VLDL2 ApoB48 (mg/dL x hr) 2.04 0.31 5.79 0.61 0.0009 2.38 1.03* 7.84 1.73*† 0.008
Fasting VLDL2 ApoB100 (mg/dL) 1.91 0.58 2.49 0.74 0.749 3.51 0.63*† 4.77 0.56*† 0.162
IAUC VLDL2ApoB100 (mg/dL x hr) 2.39 0.54 9.11 2.14 0.0001 5.87 1.56*† 16.39 2.13‡§ 0.0003
Fasting LDL C.D.(uA 234 nm/uA 200 nm x 100) 6.34 1.29 6.38 1.51 0.881 7.14 1.51 7.59 1.30 0.808
IAUC LDL C.D.(uA 234 nm/uA 200 nm x 100 x hr) 0.20 0.21 2.39 0.45 0.001 4.02 1.53‡§ 11.37 2.02‡§ 0.001
Data are presented as mean  SEM. Abbreviations: IAUC: incremental area under the curve; FFA: free fatty acids; Tg: triglyceride; C.D.: conjugated dienes.
*P  0.05 vs. controls 45TT276 GT/TT
†P  0.05 vs. controls other genotypes
§P  0.001 vs. controls 45TT276 GT/TT
‡P  0.001 vs. controls other genotypes
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accounting for the increased cardiometabolic risk of
these adiponectin SNPs.
The postprandial increase in intestinal VLDL1 and
oxLDL independently predicted the severity of liver his-
tology in our patients, thus providing a biological mech-
anism for the epidemiological association between liver
disease and atherosclerosis in NASH.1,2 Consistently,
postprandial hepatic FFA uptake contributes substan-
tially to liver Tg pool in NAFLD and diabetes in vivo.14,15
In cell cultures VLDL-Tg and oxidized LDL activated
Kupffer and stellate cells, triggering an inflammatory cas-
cade and extracellular matrix deposition34; the amount of
oxidized LDL paralleled the severity of the fibrogenic pro-
cess in NASH.35 Finally, increased intracellular oxidative
stress experimentally impaired VLDL secretion and led to
Tg accumulation in hepatocytes, an effect totally reversed
by antioxidant treatment.36
If the increased cardiovascular risk of adiponectin
SNP 45TG and 276GT with NAFLD is prospectively
confirmed by larger studies, assessing this polymor-
phisms may help in the selection of those subjects ame-
nable to more aggressive interventions targeting
postprandial lipid metabolism (i.e., statins, PPAR-al-
pha agonists). Attention should also be paid to the type
of dietary fat in addition to total calorie intake. High-
risk adiponectin genotypes might benefit from an ap-
proach combining PUFA supplementation with
insulin sensitizers.37 Furthermore, the impact of adi-
ponectin SNPs on the response to thiazolidinedione
treatment in NASH needs to be addressed in future
research.11
Limitations of this study were its cross-sectional na-
ture, preventing any causal inference, and the small num-
ber of subjects. Furthermore, our measurements were
made in patients with the progressive form of NAFLD,
that is, NASH, and need to be confirmed in subjects with
steatosis alone.
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